Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Upgraded by Wedbush

Wedbush upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) to a strong-buy rating in a report published on Monday, Zacks.com reports.

A number of other equities research analysts have also recently commented on ASND. Wells Fargo & Company raised their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. Evercore ISI boosted their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a research report on Tuesday, September 17th. Oppenheimer restated an "outperform" rating and issued a $190.00 price objective (up from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th. The Goldman Sachs Group boosted their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Finally, Jefferies Financial Group boosted their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a research report on Tuesday, August 13th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $195.92.

Ascendis Pharma A/S Price Performance

Shares of ASND stock traded up $1.23 during trading hours on Monday, reaching $129.36. 445,441 shares of the company traded hands, compared to its average volume of 444,029. The firm has a 50-day moving average price of $132.96 and a 200 day moving average price of $133.37. The company has a market cap of $7.84 billion, a P/E ratio of -13.67 and a beta of 0.66. Ascendis Pharma A/S has a 12-month low of $86.54 and a 12-month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Sell-side analysts predict that Ascendis Pharma A/S will post -7.24 EPS for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its stake in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after buying an additional 80 shares during the last quarter. Profund Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 3.0% during the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company's stock valued at $398,000 after buying an additional 85 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after buying an additional 143 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock valued at $132,000 after buying an additional 332 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 9.9% during the first quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company's stock valued at $608,000 after buying an additional 361 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.